| abstract |
The invention related to 20κ-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester, 20κ-fluoro-3β-hydroxypregna-4,17(20)-dien-21-oic acid ethyl ester, 20κ-fluoro-21-hydroxypregna-4,17(20)-dien-3-one, 20κ-fluoropregna-4,17(20)-dien-3β,21-diol and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17,20 lyase, 5α-reductase and C17-hydroxylase, and to the use of these compounds in the treatment of androgen and estrogen mediated or dependent disorders, including benign prostatic hyperplasia, prostate cancer, breast cancer and DHT-mediated disorders such as acne and hirsutism. Treatment of disorders related to the over synthesis of cortisol, for example, Cushing's Syndrome are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formulae (I). |